Literature DB >> 26334621

Circulating CD105 shows significant impact in patients of oral cancer and promotes malignancy of cancer cells via CCL20.

Chang-Han Chen1,2,3,4, Hui-Ching Chuang1,3, Yu-Tsai Lin1,3, Fu-Min Fang5,3, Chao-Cheng Huang6,3, Ching-Mei Chen6, Hui Lu1, Chih-Yen Chien7,8.   

Abstract

CD105 is rich in endothelium cells and is involved in angiogenesis. Higher microvascular density of tumor is also related to the prognosis in a variety of cancers. In this present study, patients with positive N classification, advanced T classification, advanced TNM stage, extracapsular spread of lymph nodes (ECS), and perineural invasion had significantly higher levels of peripheral vein (pCD105) and venous return from tumor (tCD105) in 71 patients with OSCC compared to 13 healthy volunteers. Those with higher pCD105 or tCD105 levels had significantly poorer 5-year disease-specific survival rate (DDS) and overall survival rate (OS). The tCD105 and pCD105 levels and ECS were the independent prognostic factors by the multivariate analysis according to the Cox regression model in 5-year DDS and OS rate. SAS and SCC4 cells treated with CD105 showed the increase in migration, invasion, and proliferation in vitro and in vivo. Furthermore, CCL20 expression participated in CD105-elicited cell motility in oral cancer cells. In conclusion, higher level of circulating CD105 is related to adverse pathological features among patients with OSCC. It is also a useful marker for evaluating the prognosis and targeting therapeutics of OSCC.

Entities:  

Keywords:  CD105; Endoglin; Metastasis; Oral cancer; Prognosis

Mesh:

Substances:

Year:  2015        PMID: 26334621     DOI: 10.1007/s13277-015-3991-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  40 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Endoglin expression is associated with poor oncologic outcome in oral and oropharyngeal carcinoma.

Authors:  Gino Marioni; Filippo Marino; Luciano Giacomelli; Claudia Staffieri; Maria Livia Mariuzzi; Elena Violino; Cosimo De Filippis
Journal:  Acta Otolaryngol       Date:  2006-06       Impact factor: 1.494

3.  A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.

Authors:  Lee S Rosen; Herbert I Hurwitz; Michael K Wong; Jonathan Goldman; David S Mendelson; William D Figg; Shawn Spencer; Bonne J Adams; Delia Alvarez; Ben K Seon; Charles P Theuer; Bryan R Leigh; Michael S Gordon
Journal:  Clin Cancer Res       Date:  2012-07-05       Impact factor: 12.531

4.  A higher CD105-assessed microvessel density and worse prognosis in elderly patients with laryngeal carcinoma.

Authors:  Gino Marioni; Alberto Staffieri; Enzo Manzato; Giovanni Ralli; Marco Lionello; Luciano Giacomelli; Vlatko Prosenikliev; Rosario Marchese-Ragona; Alessandra Busnardo; Francesco Bolzetta; Stella Blandamura
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2011-02

5.  Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome.

Authors:  Tiziana Martone; Paola Rosso; Roberto Albera; Giuseppe Migliaretti; Flavio Fraire; Lorenzo Pignataro; Giancarlo Pruneri; Graziella Bellone; Giorgio Cortesina
Journal:  Oral Oncol       Date:  2005-02       Impact factor: 5.337

Review 6.  Endoglin (CD105): a marker of tumor vasculature and potential target for therapy.

Authors:  Nikolaos A Dallas; Shaija Samuel; Ling Xia; Fan Fan; Michael J Gray; Sherry J Lim; Lee M Ellis
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

Review 7.  CD105 is important for angiogenesis: evidence and potential applications.

Authors:  Sarah E Duff; Chenggang Li; John M Garland; Shant Kumar
Journal:  FASEB J       Date:  2003-06       Impact factor: 5.191

8.  Mutation analysis in Spanish patients with hereditary hemorrhagic telangiectasia: deficient endoglin up-regulation in activated monocytes.

Authors:  Francisco Sanz-Rodriguez; Africa Fernandez-L; Roberto Zarrabeitia; Alfonso Perez-Molino; Jose R Ramírez; Eliecer Coto; Carmelo Bernabeu; Luisa M Botella
Journal:  Clin Chem       Date:  2004-09-16       Impact factor: 8.327

9.  Analysis of chemokine and chemokine receptor expression in squamous cell carcinoma of the head and neck (SCCHN) cell lines.

Authors:  Hendrik A Wolff; David Rolke; Margret Rave-Fränk; Markus Schirmer; Wolfgang Eicheler; Annegret Doerfler; Andrea Hille; Clemens F Hess; Christoph Matthias; Ralph M W Rödel; Hans Christiansen
Journal:  Radiat Environ Biophys       Date:  2010-11-18       Impact factor: 1.925

10.  Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies.

Authors:  Olivier Nolan-Stevaux; Wendy Zhong; Stacey Culp; Kathy Shaffer; Joseph Hoover; Dineli Wickramasinghe; Astrid Ruefli-Brasse
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

View more
  7 in total

1.  Prognosis of neutrophil-to-lymphocyte ratio in clinical early-stage tongue (cT1/T2N0) cancer.

Authors:  Ching-Nung Wu; Hui-Ching Chuang; Yu-Tsai Lin; Fu-Min Fang; Shau-Hsuan Li; Chih-Yen Chien
Journal:  Onco Targets Ther       Date:  2017-08-04       Impact factor: 4.147

2.  Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling.

Authors:  Xiaoling Zhang; Yan Zhang; Yanan Jia; Tingting Qin; Cuicui Zhang; Yueya Li; Chengmou Huang; Zhujun Liu; Jing Wang; Kai Li
Journal:  Cancer Biol Med       Date:  2020-05-15       Impact factor: 4.248

3.  A comparison of CD105 and CD31 expression in tumor vessels of hepatocellular carcinoma by tissue microarray and flow cytometry.

Authors:  Hongyan Qian; Liping Yang; Wenjing Zhao; Haizhen Chen; Song He
Journal:  Exp Ther Med       Date:  2018-08-01       Impact factor: 2.447

4.  CD105 Is Expressed in Ovarian Cancer Precursor Lesions and Is Required for Metastasis to the Ovary.

Authors:  Shoumei Bai; Wanhong Zhu; Lan Coffman; Anda Vlad; Lauren E Schwartz; Esther Elishaev; Ronny Drapkin; Ronald J Buckanovich
Journal:  Cancers (Basel)       Date:  2019-11-02       Impact factor: 6.639

5.  Macrophage‑derived exosomes attenuate the susceptibility of oral squamous cell carcinoma cells to chemotherapeutic drugs through the AKT/GSK‑3β pathway.

Authors:  Riki Tomita; Eri Sasabe; Ayumi Tomomura; Tetsuya Yamamoto
Journal:  Oncol Rep       Date:  2020-09-02       Impact factor: 3.906

6.  Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.

Authors:  Ming-Huei Chou; Hui-Ching Chuang; Yu-Tsai Lin; Ming-Hsien Tsai; Ying-Hsien Kao; I-Chun Lin; Tai-Lin Huang; Fu-Min Fang; Chih-Yen Chien
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

7.  Tongue Cancer Cell-Derived CCL20 Induced by Interaction With Macrophages Promotes CD163 Expression on Macrophages.

Authors:  Manabu Shigeoka; Yu-Ichiro Koma; Takayuki Kodama; Mari Nishio; Masaya Akashi; Hiroshi Yokozaki
Journal:  Front Oncol       Date:  2021-06-09       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.